Marc Puigvehí1, María-Carlota Londoño2, Xavier Torras3, Sara Lorente4, Mercedes Vergara5, Rosa Maria Morillas6, Helena Masnou6, Trinidad Serrano4, Mireia Miquel5, Adolfo Gallego3, Sabela Lens2, Jose Antonio Carrión7. 1. Liver Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 2. Liver Unit, Institut de Malalties Digestives i Metabòliques, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, Barcelona, Spain. 3. Gastroenterology Department, Hospital de La Santa Creu i Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. 4. Liver Unit, Gastroenterology Department, Hospital Clínico Lozano Blesa, Zaragoza, Spain. 5. Liver Unit, Digestive Disease Department, Parc Taulí Sabadell Hospital Universitari, Institut D'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Sabadell, Barcelona, Spain. 6. Hepatology Department, Hospital Germans Trias i Pujol, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Barcelona, Spain. 7. Liver Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. jcarrion@parcsalutmar.cat.
Abstract
BACKGROUND: Direct-acting antivirals (DAAs) show high efficacy and safety in HCV-cirrhotic patients, but most maintain clinically significant portal hypertension after sustained virological response (SVR). Non-invasive Baveno and expanded-Baveno criteria can identify patients without high-risk gastroesophageal varices (GEV) who have no need for endoscopic surveillance. However, data after SVR are scarce. We performed a multicenter study to evaluate SVR effects over GEV and diagnostic accuracy of non-invasive criteria after SVR. METHODS: HCV-cirrhotic patients receiving DAAs and baseline endoscopic evaluation were included (November 2014-October 2015). GEV were classified as low risk (LR-GEV) (< 5 mm) or high risk (HR-GEV) (≥ 5 mm or with risk signs). Transient elastography (TE) and endoscopy were performed during follow-up. RESULTS: SVR was achieved in 230 (93.1%) of 247 included patients, 151 (65.7%) with endoscopic follow-up. Among 64/151 (42.4%) patients without baseline GEV, 8 (12.5%) developed GEV after SVR. Among 50/151 (33.1%) with baseline LR-GEV, 12 (24%) developed HR-GEV. Patients with GEV progression showed TE ≥ 25 kPa before treatment (64.7%) or ≥ 20 kPa after SVR (66.7%). Only 6% of patients without GEV and LSM < 25 kPa before treatment, and 10% of those with baseline LSM < 25 kPa and LSM < 20 kPa after SVR showed GEV progression after 36 months. The negative predictive value of Baveno and expanded-Baveno criteria to exclude HR-GEV was maintained after SVR (100% and 90.7%, respectively). CONCLUSIONS: HCV-cirrhotic patients can develop HR-GEV after SVR. Surveillance is especially recommended in those with GEV before antiviral treatment. Baveno and expanded-Baveno criteria can be safely applied after SVR. https://clinicaltrials.gov: NCT02758509.
BACKGROUND: Direct-acting antivirals (DAAs) show high efficacy and safety in HCV-cirrhotic patients, but most maintain clinically significant portal hypertension after sustained virological response (SVR). Non-invasive Baveno and expanded-Baveno criteria can identify patients without high-risk gastroesophageal varices (GEV) who have no need for endoscopic surveillance. However, data after SVR are scarce. We performed a multicenter study to evaluate SVR effects over GEV and diagnostic accuracy of non-invasive criteria after SVR. METHODS: HCV-cirrhotic patients receiving DAAs and baseline endoscopic evaluation were included (November 2014-October 2015). GEV were classified as low risk (LR-GEV) (< 5 mm) or high risk (HR-GEV) (≥ 5 mm or with risk signs). Transient elastography (TE) and endoscopy were performed during follow-up. RESULTS: SVR was achieved in 230 (93.1%) of 247 included patients, 151 (65.7%) with endoscopic follow-up. Among 64/151 (42.4%) patients without baseline GEV, 8 (12.5%) developed GEV after SVR. Among 50/151 (33.1%) with baseline LR-GEV, 12 (24%) developed HR-GEV. Patients with GEV progression showed TE ≥ 25 kPa before treatment (64.7%) or ≥ 20 kPa after SVR (66.7%). Only 6% of patients without GEV and LSM < 25 kPa before treatment, and 10% of those with baseline LSM < 25 kPa and LSM < 20 kPa after SVR showed GEV progression after 36 months. The negative predictive value of Baveno and expanded-Baveno criteria to exclude HR-GEV was maintained after SVR (100% and 90.7%, respectively). CONCLUSIONS: HCV-cirrhotic patients can develop HR-GEV after SVR. Surveillance is especially recommended in those with GEV before antiviral treatment. Baveno and expanded-Baveno criteria can be safely applied after SVR. https://clinicaltrials.gov: NCT02758509.
Authors: Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant Journal: Arterioscler Thromb Vasc Biol Date: 2004-02 Impact factor: 8.311
Authors: Mattias Mandorfer; Karin Kozbial; Philipp Schwabl; Clarissa Freissmuth; Rémy Schwarzer; Rafael Stern; David Chromy; Albert Friedrich Stättermayer; Thomas Reiberger; Sandra Beinhardt; Wolfgang Sieghart; Michael Trauner; Harald Hofer; Arnulf Ferlitsch; Peter Ferenci; Markus Peck-Radosavljevic Journal: J Hepatol Date: 2016-05-27 Impact factor: 25.083
Authors: Salvador Augustin; Mònica Pons; James B Maurice; Christophe Bureau; Horia Stefanescu; Michel Ney; Hélène Blasco; Bogdan Procopet; Emmanuel Tsochatzis; Rachel H Westbrook; Jaime Bosch; Annalisa Berzigotti; Juan G Abraldes; Joan Genescà Journal: Hepatology Date: 2017-10-30 Impact factor: 17.425
Authors: Marc Puigvehí; Teresa Broquetas; Susanna Coll; Montserrat Garcia-Retortillo; Nuria Cañete; Rosa Fernández; Javier Gimeno; Juan Sanchez; Felipe Bory; Juan Pedro-Botet; Ricard Solà; José A Carrión Journal: J Gastroenterol Hepatol Date: 2017-10 Impact factor: 4.029
Authors: Thomas Reiberger; Arnulf Ferlitsch; Berit Anna Payer; Matthias Pinter; Philipp Schwabl; Judith Stift; Michael Trauner; Markus Peck-Radosavljevic Journal: Wien Klin Wochenschr Date: 2012-06-15 Impact factor: 1.704